KEYNOTE-B49 at #ESMO26
In pretreated HR+/HER2− metastatic breast cancer, pembrolizumab + chemotherapy improved PFS (HR 0.74; 6.7 vs 6.0 months), with 99% previously exposed to CDK4/6 inhibitors.
https://www.annalsofoncology.org/article/S0923-7534(26)08077-4/abstract
#BreastCancer @OncoAlert #BCSM @myESMO
90 浏览 · 6 赞 · 4 转发 · 1 回复
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@OncoAlert @myESMO The 24-month PFS rates (14.1% vs 3.5%) suggest durable control in a subset. However, the modest median gain, immune-related toxicity, and pending mature OS data warrant caution before routine adoption.
来源：Aya Mohamed | MSc, MD 🎗 · x.com